HIV cell ther­a­py biotech Ad­dim­mune to go pub­lic via SPAC merg­er; WHO names new Covid-19 'vari­ant of in­ter­est'

Ad­dim­mune, a biotech that is work­ing on a cell ther­a­py for HIV, an­nounced Wednes­day that it plans to merge with 10X Cap­i­tal Ven­ture’s SPAC to be­come a pub­lic com­pa­ny. The biotech in­tends to trade un­der the tick­er $HIV.

The merg­er val­ues Ad­dim­mune at about $500 mil­lion. Ad­dim­mune spun out of Amer­i­can Gene Tech­nolo­gies in June, tak­ing the ex­per­i­men­tal HIV ther­a­py with it. Jeff Galvin, who is CEO of Amer­i­can Gene Tech­nolo­gies, is al­so CEO of Ad­dim­mune.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER